EraGen clears patent dispute to focus on R&D (Research and Development)
This article was originally published in Clinica
Executive Summary
EraGen BioSciences (Madison, Wisconsin) has reached a settlement in its patent dispute with larger rival, Third Wave Technologies (also of Madison). "We decided our funds are better spent on R&D and introducing new products, than on protracted litigation with a larger, better funded competitor," said Irene Hrusovsky, EraGen president and CEO.